top of page
%201.png)
© 2026 Damu Therapeutics.
Our Platform
We are building a precision screening platform for hemoglobin. By combining high-throughput compound screening with solution-state NMR mapping, we identify and optimize binding interactions at the molecular level — starting with sickle cell disease.
Human Hemoglobin Source
We isolate hemoglobin from donated human blood to ensure physiological relevance from the earliest stage of discovery. By working with the authentic human blood at an early stage, we are testing in the tissue where the drug needs to function.
High-Throughput Screening
Thousands of small molecules are screened directly against hemoglobin in solution to identify true binding interactions. Rather than pre-selecting a single binding site, we allow compounds to interact across the entire protein surface.
Solution-State NMR Mapping
We produce the protein hemoglobin recombinantly for use in solution-phase NMR. By studying the protein in solution, we preserve its natural structure and cell behavior. We determine where compounds bind and quantify binding strength. This dynamic approach captures transient and flexible interactions that static crystal structures may overlook.
Translational Validation
Promising binders are evaluated in functional hemoglobin assays and established sickle cell mouse models to assess biological impact. This step bridges molecular discovery with real-world therapeutic potential.
bottom of page